ADMA Biologics publishes data showing optimized IVIG process reduces impurities linked to thrombosis risk.
ADMA Biologics announced a peer-reviewed publication revealing that its optimized intravenous immune globulin (IVIG) manufacturing process effectively removes procoagulant impurities associated with thromboembolic events while maintaining immunoglobu...
